{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T09:06:32Z","timestamp":1780131992996,"version":"3.54.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100005187","name":"University of Athens","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005187","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s11523-026-01221-4","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T13:46:23Z","timestamp":1778247983000},"page":"421-432","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Indirect Comparison of the Efficacy of Pembrolizumab Versus Nivolumab as Adjuvant Options for Stage IIB\/IIC Melanoma"],"prefix":"10.1007","volume":"21","author":[{"given":"Dimitrios A.","family":"Andreikos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iro","family":"Argyropoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampos","family":"Theocharopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalia","family":"Anastasopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Stefanou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgos","family":"Lyrarakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Gogas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2620-4004","authenticated-orcid":false,"given":"Dimitrios C.","family":"Ziogas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"1221_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s13555-016-0165-y","volume":"7","author":"Z Apalla","year":"2017","unstructured":"Apalla Z, Nashan D, Weller RB, Castellsagu\u00e9 X. Skin cancer: epidemiology, disease burden, pathophysiology, diagnosis, and therapeutic approaches. Dermatol Ther. 2017;7:5\u201319. https:\/\/doi.org\/10.1007\/s13555-016-0165-y.","journal-title":"Dermatol Ther"},{"key":"1221_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/pcmr.12172","volume":"27","author":"RR Braeuer","year":"2014","unstructured":"Braeuer RR, Watson IR, Wu C, Mobley AK, Kamiya T, Shoshan E, et al. Why is melanoma so metastatic? Pigment Cell Melanoma Res. 2014;27:19\u201336. https:\/\/doi.org\/10.1111\/pcmr.12172.","journal-title":"Pigment Cell Melanoma Res"},{"key":"1221_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.0160","volume":"158","author":"M Arnold","year":"2022","unstructured":"Arnold M, Singh D, Laversanne M, Vignat J, Vaccarella S, Meheus F, et al. Global burden of cutaneous melanoma in 2020 and projections to 2040. JAMA Dermatol. 2022;158:495. https:\/\/doi.org\/10.1001\/jamadermatol.2022.0160.","journal-title":"JAMA Dermatol"},{"key":"1221_CR4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"1221_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.3256","volume":"159","author":"NM Helvind","year":"2023","unstructured":"Helvind NM, Brinch-M\u00f8ller Weitemeyer M, Chakera AH, Hendel HW, Elleb\u00e6k E, Svane IM, et al. Stage-specific risk of recurrence and death from melanoma in Denmark, 2008-2021: a national observational cohort study of 25 720 patients with stage IA to IV melanoma. JAMA Dermatol. 2023;159:1213. https:\/\/doi.org\/10.1001\/jamadermatol.2023.3256.","journal-title":"JAMA Dermatol"},{"key":"1221_CR6","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1200\/JCO.22.00202","volume":"40","author":"C Garbe","year":"2022","unstructured":"Garbe C, Keim U, Amaral T, Berking C, Eigentler TK, Flatz L, et al. Prognosis of patients with primary melanoma stage I and II according to American Joint Committee on Cancer version 8 validated in two independent cohorts: implications for adjuvant treatment. J Clin Oncol. 2022;40:3741\u20139. https:\/\/doi.org\/10.1200\/JCO.22.00202.","journal-title":"J Clin Oncol"},{"key":"1221_CR7","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3322\/caac.21409","volume":"67","author":"JE Gershenwald","year":"2017","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, et al. Melanoma staging: evidence\u2010based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:472\u201392. https:\/\/doi.org\/10.3322\/caac.21409.","journal-title":"CA Cancer J Clin"},{"key":"1221_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1197","volume":"13","author":"RP Patel","year":"2023","unstructured":"Patel RP, Somasundram PM, Smith LK, Sheppard KE, McArthur GA. The therapeutic potential of targeting minimal residual disease in melanoma. Clin Transl Med. 2023;13:e1197. https:\/\/doi.org\/10.1002\/ctm2.1197.","journal-title":"Clin Transl Med"},{"key":"1221_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2024.11.006","volume":"36","author":"T Amaral","year":"2025","unstructured":"Amaral T, Ottaviano M, Arance A, Blank C, Chiarion-Sileni V, Donia M, et al. Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025;36:10\u201330. https:\/\/doi.org\/10.1016\/j.annonc.2024.11.006.","journal-title":"Ann Oncol"},{"key":"1221_CR10","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","volume":"399","author":"JJ Luke","year":"2022","unstructured":"Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022;399:1718\u201329. https:\/\/doi.org\/10.1016\/S0140-6736(22)00562-1.","journal-title":"Lancet"},{"key":"1221_CR11","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1038\/s41591-023-02583-2","volume":"29","author":"JM Kirkwood","year":"2023","unstructured":"Kirkwood JM, Del Vecchio M, Weber J, Hoeller C, Grob J-J, Mohr P, et al. Adjuvant nivolumab in resected stage IIB\/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nat Med. 2023;29:2835\u201343. https:\/\/doi.org\/10.1038\/s41591-023-02583-2.","journal-title":"Nat Med"},{"key":"1221_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115381","volume":"220","author":"JJ Luke","year":"2025","unstructured":"Luke JJ, Ascierto PA, Khattak MA, Rutkowski P, Del Vecchio M, Spagnolo F, et al. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study. Eur J Cancer. 2025;220:115381. https:\/\/doi.org\/10.1016\/j.ejca.2025.115381.","journal-title":"Eur J Cancer"},{"key":"1221_CR13","doi-asserted-by":"publisher","first-page":"S952","DOI":"10.1016\/j.annonc.2025.08.2238","volume":"36","author":"JM Kirkwood","year":"2025","unstructured":"Kirkwood JM, Del Vecchio M, Hoeller C, Mohr P, Grabbe S, Dutriaux C, et al. 1610P adjuvant nivolumab vs placebo in resected stage IIB\/C melanoma: 4-year update from CheckMate 76K. Ann Oncol. 2025;36:S952\u20133. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.2238.","journal-title":"Ann Oncol"},{"key":"1221_CR14","unstructured":"US Food and Drug Administration. FDA approves pembrolizumab for adjuvant treatment of stage IIB or IIC melanoma. 2021. http:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda. Accessed 1 Aug 2025. Cited 1 Aug 2025."},{"key":"1221_CR15","unstructured":"US Food and Drug Administration. FDA approves nivolumab for adjuvant treatment of Stage IIB\/C melanoma. 2023. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-nivolumab-adjuvant-treatment-stage-iibc-melanoma. Accessed 1 Aug 2025. Cited 1 Aug 2025."},{"key":"1221_CR16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/jnci\/djx133","volume":"110","author":"S Suciu","year":"2018","unstructured":"Suciu S, Eggermont AMM, Lorigan P, Kirkwood JM, Markovic SN, Garbe C, et al. Relapse-free survival as a surrogate for overall survival in the evaluation of stage II\u2013III melanoma adjuvant therapy. JNCI J Natl Cancer Inst. 2018;110:87\u201396. https:\/\/doi.org\/10.1093\/jnci\/djx133.","journal-title":"JNCI J Natl Cancer Inst"},{"key":"1221_CR17","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ejca.2020.07.011","volume":"137","author":"E Coart","year":"2020","unstructured":"Coart E, Suciu S, Squifflet P, Saad ED, Moshyk A, De Schaetzen G, et al. Evaluating the potential of relapse-free survival as a surrogate for overall survival in the adjuvant therapy of melanoma with checkpoint inhibitors. Eur J Cancer. 2020;137:171\u20134. https:\/\/doi.org\/10.1016\/j.ejca.2020.07.011.","journal-title":"Eur J Cancer"},{"key":"1221_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14369","volume":"8","author":"S Tan","year":"2017","unstructured":"Tan S, Zhang H, Chai Y, Song H, Tong Z, Wang Q, et al. An unexpected N-terminal loop in PD-1 dominates binding by nivolumab. Nat Commun. 2017;8:14369. https:\/\/doi.org\/10.1038\/ncomms14369.","journal-title":"Nat Commun"},{"key":"1221_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-72118-3","volume":"14","author":"A Gordeev","year":"2024","unstructured":"Gordeev A, Vaal A, Puchkova M, Smirnova I, Doronin A, Znobishcheva A, et al. Preclinical comparison of prolgolimab, pembrolizumab and nivolumab. Sci Rep. 2024;14:23136. https:\/\/doi.org\/10.1038\/s41598-024-72118-3.","journal-title":"Sci Rep"},{"key":"1221_CR20","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4508","volume":"6","author":"J Portnow","year":"2020","unstructured":"Portnow J, Wang D, Blanchard MS, Tran V, Alizadeh D, Starr R, et al. Systemic anti\u2013PD-1 immunotherapy results in PD-1 blockade on T cells in the cerebrospinal fluid. JAMA Oncol. 2020;6:1947. https:\/\/doi.org\/10.1001\/jamaoncol.2020.4508.","journal-title":"JAMA Oncol"},{"key":"1221_CR21","doi-asserted-by":"publisher","first-page":"410","DOI":"10.7150\/jca.17144","volume":"8","author":"L Guo","year":"2017","unstructured":"Guo L, Zhang H, Chen B. Nivolumab as programmed death-1 (PD-1) inhibitor for targeted immunotherapy in tumor. J Cancer. 2017;8:410\u20136. https:\/\/doi.org\/10.7150\/jca.17144.","journal-title":"J Cancer"},{"key":"1221_CR22","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","volume":"28","author":"JR Brahmer","year":"2010","unstructured":"Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti\u2013programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167\u201375. https:\/\/doi.org\/10.1200\/JCO.2009.26.7609.","journal-title":"J Clin Oncol"},{"key":"1221_CR23","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/CMR.0000000000000885","volume":"33","author":"B Cybulska-Stopa","year":"2023","unstructured":"Cybulska-Stopa B, Piejko K, Ostaszewski K, Dziura R, Galus \u0141, Zi\u00f3\u0142kowska B, et al. Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment. Melanoma Res. 2023;33:208\u201317. https:\/\/doi.org\/10.1097\/CMR.0000000000000885.","journal-title":"Melanoma Res"},{"key":"1221_CR24","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1080\/0284186X.2020.1712473","volume":"59","author":"JC Moser","year":"2020","unstructured":"Moser JC, Wei G, Colonna SV, Grossmann KF, Patel S, Hyngstrom JR. Comparative-effectiveness of pembrolizumab vs. nivolumab for patients with metastatic melanoma. Acta Oncol. 2020;59:434\u20137. https:\/\/doi.org\/10.1080\/0284186X.2020.1712473.","journal-title":"Acta Oncol"},{"key":"1221_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-70207-7","volume":"10","author":"P Cui","year":"2020","unstructured":"Cui P, Li R, Huang Z, Wu Z, Tao H, Zhang S, et al. Comparative effectiveness of pembrolizumab vs. nivolumab in patients with recurrent or advanced NSCLC. Sci Rep. 2020;10:13160. https:\/\/doi.org\/10.1038\/s41598-020-70207-7.","journal-title":"Sci Rep"},{"key":"1221_CR26","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim D-W, Felip E, P\u00e9rez-Gracia JL, Han J-Y, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(15)01281-7.","journal-title":"Lancet"},{"key":"1221_CR27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.lungcan.2022.03.020","volume":"167","author":"M Torasawa","year":"2022","unstructured":"Torasawa M, Yoshida T, Yagishita S, Shimoda Y, Shirasawa M, Matsumoto Y, et al. Nivolumab versus pembrolizumab in previously-treated advanced non-small cell lung cancer patients: a propensity-matched real-world analysis. Lung Cancer. 2022;167:49\u201357. https:\/\/doi.org\/10.1016\/j.lungcan.2022.03.020.","journal-title":"Lung Cancer"},{"key":"1221_CR28","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1002\/ijc.31136","volume":"142","author":"F Passiglia","year":"2018","unstructured":"Passiglia F, Galvano A, Rizzo S, Incorvaia L, List\u00ec A, Bazan V, et al. Looking for the best immune\u2010checkpoint inhibitor in pre\u2010treated NSCLC patients: an indirect comparison between nivolumab, pembrolizumab and atezolizumab. Int J Cancer. 2018;142:1277\u201384. https:\/\/doi.org\/10.1002\/ijc.31136.","journal-title":"Int J Cancer"},{"key":"1221_CR29","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.intimp.2017.05.019","volume":"49","author":"T-R Peng","year":"2017","unstructured":"Peng T-R, Tsai F-P, Wu T-W. Indirect comparison between pembrolizumab and nivolumab for the treatment of non-small cell lung cancer: a meta-analysis of randomized clinical trials. Int Immunopharmacol. 2017;49:85\u201394. https:\/\/doi.org\/10.1016\/j.intimp.2017.05.019.","journal-title":"Int Immunopharmacol"},{"key":"1221_CR30","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.8065","volume":"4","author":"R Pei","year":"2021","unstructured":"Pei R, Shi Y, Lv S, Dai T, Zhang F, Liu S, et al. Nivolumab vs pembrolizumab for treatment of US patients with Platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma: a network meta-analysis and cost-effectiveness analysis. JAMA Netw Open. 2021;4:e218065. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.8065.","journal-title":"JAMA Netw Open"},{"key":"1221_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11298-z","volume":"23","author":"Y-H Chen","year":"2023","unstructured":"Chen Y-H, Tsai C-H, Chen Y-Y, Wang C-C, Wang J-H, Hung C-H, et al. Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma. BMC Cancer. 2023;23:810. https:\/\/doi.org\/10.1186\/s12885-023-11298-z.","journal-title":"BMC Cancer"},{"key":"1221_CR32","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","volume":"50","author":"HC Bucher","year":"1997","unstructured":"Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50:683\u201391. https:\/\/doi.org\/10.1016\/S0895-4356(97)00049-8.","journal-title":"J Clin Epidemiol"},{"key":"1221_CR33","unstructured":"Green SHJPT. Cochrane handbook for systematic reviews of interventions [Internet]. The Cochrane Collaboration. http:\/\/training.cochrane.org\/handbook."},{"key":"1221_CR34","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","volume":"5","author":"Y Wang","year":"2019","unstructured":"Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol. 2019;5:1008\u201319. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0393.","journal-title":"JAMA Oncol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01221-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01221-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01221-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T08:54:55Z","timestamp":1780131295000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-026-01221-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1221"],"URL":"https:\/\/doi.org\/10.1007\/s11523-026-01221-4","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"26 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for the final version to be published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship"}},{"value":"Dirk Schadendorf: financial interests, personal, invited speaker: BMS, MSD, Merck Serono, and Regeneron; financial interests, personal, advisory board: BMS, Novartis, MSD, Immunocore, Pierre Fabre, Regeneron, Philogen, BioAlta, Daiichi Sankyo, BioNTech, Immatics, CureVac, Formycon, Replimune, Sunpharma, Skyline Dx, IOVance, Ipsen, IOBioTech, and Boehringer Ingelheim; financial interests, institutional, coordinating PI: Novartis, BMS, MSD, Pierre Fabre, and Immatics; financial interests, institutional, research grant: BMS and MSD; financial interests, personal, steering committee member: MSD; financial interests, institutional, local PI: Philogen, Immunocore, Regeneron, BioNTech RNA Pharmaceuticals GMBH, Replimune, and IO Biotech; nonfinancial interests, personal, member of board of directors: EORTC-MG; nonfinancial interests, personal, leadership role, founding member and SC chair: European Melanoma Registry (EuMelaReg). Helen Gogas: financial interests, personal, advisory board: MSD, BMS, Pierre Fabre, and Sanofi; financial interests, personal, invited speaker: MSD, BMS, Novartis, Pierre Fabre, and Sanofi; financial interests, personal, steering committee member: Amgen and Replimune; financial interests, institutional, local Pi: Amgen, MSD, BMS, Replimune, Iovance, and Bayer; financial interests, institutional, research grant: BMS, Pfizer, Lilly, Pierre Fabre, and AstraZeneca. Dimitrios C. Ziogas: financial interests, personal, invited speaker: AstraZeneca, MSD, BMS, Ipsen, Pierre Fabre, Gilead, Amgen, and Genesis; financial interests, personal, advisory board: Roche and Winmedica. Dimitrios A. Andreikos, Iro Argyropoulou, Charalampos Theocharopoulos, Amalia Anastasopoulou, Dimitra Stefanou, and Giorgos Lyrarakis declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate, Consent to Publish"}},{"value":"All data generated or analyzed during this study are included in this published article\/as supplementary information files.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' Contributions"}}]}}